Change in 21-gene recurrence score (RS) (Oncotype DX) after exposure to neoadjuvant endocrine therapy.

被引：0

作者：

Hilal, Talal

Mi, Lanyu

Anderson, Karen S.

Pockaj, Barbara A.

Gray, Richard J.

Dixon, Leslie E.

Martinez, Erika D.

Singh, Charanjit

Northfelt, Donald W.

机构：

[1] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Phoenix, AZ USA

[2] Mayo Clin, Phoenix, AZ USA

[3] Arizona State Univ, Temple, TX USA

[4] Mayo Clin Arizona, Scottsdale, AZ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e12650

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e12650

引用

页数：2

共 50 条

[1] Use of the 21-gene Oncotype DX® Breast Recurrence Score™ (RS) assay in the neoadjuvant treatment setting
Robidoux, A.
McCullough, D.
Lau, A.
Stoppler, M.
Chao, C.
BREAST, 2017, 32 : S80 - S80
[2] Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence between Breast Cancer Index (BCI) and 21-gene Oncotype DX Recurrence Score (RS)
Patel, Rima
Casasanta, Nicole
Li, Zhiqiang
Kier, Melanie
Blanter, Julia
Sohval, Sophie
Hovstadius, Malin
Wu, Catherine
Fink, Marc
Zhou, Xiang
Zimmerman, Brittney
Cascetta, Krystal
Chen, Rong
Oh, William
Tiersten, Amy
CANCER RESEARCH, 2023, 83 (05)
[3] Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Casasanta, Nicole
Patel, Rima
Raymond, Samantha
Kier, Melanie W.
Blanter, Julia
Sohval, Sophie
Hovstadius, Malin
Wu, Catherine
Zimmerman, Brittney
Cascetta, Krystal
Bagiella, Emilia
Tiersten, Amy
CLINICAL BREAST CANCER, 2024, 24 (07) : 585 - 596
[4] Evaluation oncotype DX® 21-gene recurrence score and clinicopathological parameters: a single institutional experience
Lashen, Ayat
Toss, Michael S.
Fadhil, Wakkas
Oni, Georgette
Madhusudan, Srinivasan
Rakha, Emad
HISTOPATHOLOGY, 2023, 82 (05) : 755 - 766
[5] 21-Gene Oncotype DX® Recurrence-Score benefits and application in elderly breast cancer patients
Chiru, E. D.
Kuhar, C. Grasic
Oseledchyk, A.
Kurzeder, C.
Vetter, M.
SWISS MEDICAL WEEKLY, 2022, 152 : 43S - 43S
[6] Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes
Giridhar, Karthik V.
Choong, Grace M.
Yadav, Siddartha
Polley, Eric C.
Leon-Ferre, Roberto A.
Liu, Minetta C.
Goetz, Matthew P.
Couch, Fergus J.
CANCER RESEARCH, 2020, 80 (04)
[7] Evaluation Oncotype DX® 21-Gene Recurrence Score and clinicopathological parameters in early stage breast cancer
Lashen, A. L.
Toss, M. T.
Fadhil, W. F.
Oni, G. O.
Madhusudan, S. M.
Rakha, E. R.
JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
[8] Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer
Hilal, Talal
Mi, Lanyu
Ertz-Archambault, Natalie M.
Almquist, Daniel R.
Anderson, Karen S.
Gray, Richard J.
Pockaj, Barbara A.
Northfelt, Donald W.
BREAST JOURNAL, 2020, 26 (07): : 1449 - 1451
[9] Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Buus, Richard
Sestak, Ivana
Kronenwett, Ralf
Denkert, Carsten
Dubsky, Peter
Krappmann, Kristin
Scheer, Marsel
Petry, Christoph
Cuzick, Jack
Dowsett, Mitch
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (11):
[10] Identifying anatomopathological factors associated with a Oncotype DX 21-gene recurrence score higher than 25 in menopaused women
Guerif, Clara
Jamelot, Mathieu
Kebir, Fatima
Zilberman, Sonia
Seknazi, Lauren
Barthere, Xavier
De Forceville, Louise
Theodore, Claire
Touboul, Cyril
Buob, David
Gligorov, Joseph
Benderra, Marc Antoine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →